Agendia Boasts Expanded Clearance, Reimbursement For Breast Cancer Test
This article was originally published in The Gray Sheet
Executive Summary
Gene expression test maker Agendia will ramp up its U.S. marketing efforts after gaining expanded FDA clearance and Medicare coverage for its flagship MammaPrint breast cancer recurrence test